A Rare Case of Primary Hyperparathyroidism Caused by a Giant Solitary Parathyroid Adenoma

ABEFG 1 Ioannis Mantzoros
ABCD 1 Despoina Kyriakidou
CDEF 1 Konstantinos Galanos-Demiris
CDEF 1 Christos Chatzakis
ABE 1 Styliani Parpoudi
ADE 2 Nikolaos Sapidis
BCF 1 Lydia Loutzidou
ABDE 1 Orestis Ioannidis
AE 1 Stamatis Angelopoulos
AE 1 Konstantinos G. Tsalis

Corresponding Author: Ioannis Mantzoros, e-mail: imanvol@gmail.com
Conflict of interest: None declared

Patient: Female, 73
Final Diagnosis: Primary hyperparathyroidism
Symptoms: Bone fractures • nephrolithiasis • palpable mass • weakness
Medication: —
Clinical Procedure: Operation
Specialty: Surgery

Objective: Rare disease
Background: Solitary parathyroid adenomas are the leading cause of primary hyperparathyroidism in 0% to 85% of cases. Diagnosis of parathyroid adenoma is based on typical clinical presentation of hypercalcemia, biochemical profile, and modern imaging studies. The purpose of this article is to present the diagnostic and therapeutic approach used for a 73-year-old female patient with a giant parathyroid adenoma measuring 5×2.5×2.5 cm and weighing 30 grams.

Case Report: A 73-year-old female was referred to the outpatient clinic of our Surgical Department with the diagnosis of primary hyperparathyroidism. The patient suffered from typical symptoms of hypercalcemia such as weakness, bone disease, and recurrent nephrolithiasis; she had a painless cervical mass for 5 months. Primary hyperparathyroidism was confirmed based on the patient’s biochemical profile, which showed increased levels of serum calcium and parathyroid hormone. SestaMIBI scintigraphy with $^{99m}$Tc-Technetium and cervical ultrasonography revealed a large nodule at the inferior pole of the right lobe of the thyroid gland. Intraoperatively, a giant parathyroid adenoma was found and excised. Additionally, levels of intact parathyroid hormone (IOiPTH) were determined intraoperatively and a 95% reduction was found, 20 minutes after the removal of the adenoma.

Conclusions: This is an extremely rare case of a giant solitary parathyroid adenoma. Diagnosis of a giant hyperfunctioning solitary parathyroid adenomas was based on clinical presentation, biochemical profile, and imaging studies. Selective treatment was based on surgical excision combined with IOiPTH levels measurement.

MeSH Keywords: Adenoma • Hyperparathyroidism • Parathyroid Neoplasms

Full-text PDF: https://www.amjcaserep.com/abstract/index/idArt/911452
Background

Prevalence of primary hyperparathyroidism is approximately 1–7 per 1000 in the general population, affecting predominantly postmenopausal women. The leading cause of primary hyperparathyroidism is the solitary parathyroid adenoma in 80% to 85% of cases [1–3]. Secondary causes include parathyroid hyperplasia (10% to 15% of cases), multiple adenomas (5% of cases) and rarely parathyroid cancer (<1% to 5% of cases) [1,2]. Primary hyperparathyroidism shows a similar incidence for males and females before the age of 45 years; however, it presents a clear female predominance with ratio 3:1 around the seventh decade of life [4–6].

Usually, parathyroid adenomas are small in size and weigh less than 1 gram [2]. Rarely adenomas can become rather large and weigh more than 3.5 grams. Those adenomas are characterized as “giant” [7].

Hyperparathyroidism is suspected when characteristic clinical signs and symptoms are present, such as neuromuscular weakness, bone disease, recurrent nephrolithiasis, and psychiatric disorders [8,9]. The diagnosis is based on elevated levels of serum calcium and parathyroid hormone (PTH). Moreover, modern imaging techniques, such as cervical ultrasonography (US), sestaMIBI scintigraphy and magnetic resonance imaging (MRI), are routinely used for the localization of the adenoma.

Treatment of choice is the excision of the adenoma. Minimal invasive parathyroidectomy (MIP) in combination with intraoperative measurement of intact parathyroid hormone (IOiPTH) levels is the optimal surgical approach [4].

Case Report

A 73-year-old female patient was referred to our Surgical Department due to a palpable painless mass on her neck noticed for the last 5 months. The patient also suffered from fatigue and recurrent pain in the left ankle for the last 3 months. Her past medical history revealed recurrent nephrolithiasis treated with ESWL (extracorporeal shock wave lithotripsy) 7 years ago.

Her initial blood examination revealed hypercalcemia (Ca++=14.5 mg/dL) and mild hypophosphatemia (P=2.4 mg/dL). These results led us to measure the levels of serum PTH, which was remarkably elevated (1629 pg/mL), therefore, the diagnosis of primary hyperparathyroidism was established. Thyroid hormones and tumor markers were normal. The patient suffered also from anemia (Hematocrit=29%) and elevated levels of C-reactive protein (CRP) and ferritin. Cervical US revealed a hypoechoic nodule at the inferior pole of the right lobe of the thyroid gland. SestaMIBI scintigraphy with 99mTc revealed a hyperfunctioning right lower parathyroid gland.

The patient underwent a MIP and a giant parathyroid adenoma was found at the inferior pole of the right lobe of the thyroid gland and was excised (Figures 1, 2). Its dimensions were 5×2.5×2.5 cm and it weighed 30 grams. IOiPTH levels were measured and revealed a gradual reduction after the removal of the adenoma. The values were 1415 pg/mL immediately after excision, 739 pg/mL 10 minutes after excision, and 57 pg/mL 20 minutes later (Table 1).

Table 1. Intra-operative PTH levels.

| PTH level (pg/mL) | Time after excision |
|-------------------|---------------------|
| 1415              | 0 min               |
| 739               | 10 min              |
| 57                | 20 min              |

IOiPTH levels were measured immediately after the removal of the adenoma, 10 minutes after excision, and 20 minutes later.
Histological examination confirmed the diagnosis of a parathyroid adenoma with no signs of malignancy. Hungry bone syndrome presented immediately after operation. The patient presented low levels of serum calcium (Ca²⁺=8.2 mg/dL) and the next postoperative day (Ca²⁺=7.8 mg/dL) and expressed mild symptoms of tetany. The syndrome was initially treated with intravenous calcium in the first postoperative day and oral calcium and vitamin A for a week after operation. Postoperative PTH levels, serum calcium, and serum phosphate were normal 10 days after the operation and 6 months later. Patient's symptoms were also resolved after successful treatment.

Discussion

In most cases of primary hyperparathyroidism due to solitary parathyroid adenoma, the adenoma is usually small in size and weighs less than 1 gram [2]. Very few cases have been reported in the literature in which the adenoma weighed more than 3.5 grams. These adenomas are usually referred as “giant”. The presence of a huge adenoma such as our patient’s that weighed 30 grams is very rare and it is questionable whether such a huge adenoma has ever been reported [7].

Primary hyperparathyroidism presents with a variety of symptoms such as neuromuscular weakness, fatigue, bone disease, recurrent nephrolithiasis and nephrocalcinosis, psychiatric disorders, decreased concentration and memory loss, nausea, vomiting, constipation and bradycardia [8–12]. During the last decades, patients have presented with profound symptoms of severe hypercalcemia and bone disease. Moreover, dehydration has led many patients to hypercalcemic crisis, a condition related to sudden increase of serum calcium levels that causes abdominal pain, nausea, vomiting, constipation and bradycardia [12]. Nevertheless, the increased use of biochemical screening tests contributed to incidental identification of patients with slightly elevated serum calcium levels and milder symptoms [6]. On the other hand, a palpable parathyroid adenoma is very rare. In our case, apart from clinical findings depending on the serum calcium levels, a palpable mass was obvious on the patient’s neck. Cases of palpable parathyroid adenoma are extremely rare in the published literature.

Biochemical findings showing high levels of serum calcium and increased levels of PTH are essential for the diagnosis.

Clinical suspicion and laboratory findings are followed by imaging studies, which confirm the diagnosis. Cervical US is widely used to locate the pathologic gland with an approximate sensitivity and specificity of 75% and 85% respectively [13]. MRI and four-dimensional computed tomography (4D-CT) scan are routinely used to identify the cause of hyperparathyroidism and to detect ectopic parathyroid tissue. ⁹⁹ᵐTc-MIBI (sesta-MIBI) scintigraphy utilizes the absorption of the radiotracer to detect hyperactive parathyroid tissue and has a sensitivity rate between 70% to 100% [14]. Preoperative localization of the adenoma is crucial in order to achieve the optimal surgical outcome and the combination of sestaMIBI scintigraphy and cervical US are considered the best way to delineate the anatomic correlations of an adenoma [15]. We used all these radiologic and laboratory tests in order to confirm the diagnosis and localize the adenoma. Although the adenoma was palpable, full radiologic exploration of the mass was necessary in order to define this extremely rare case of hyperparathyroidism.

The definitive treatment of primary hyperparathyroidism is the surgical resection of all pathologic parathyroid tissue. Since Dr. Felix Mandl performed the first successful parathyroidectomy in 1925, bilateral neck exploration has been the gold standard with cure rates exceeding 95% [16,17]. Excision of the pathologic parathyroid tissue is achieved either through bilateral neck exploration or via MIP [18,19]. In the first method, all four parathyroid glands are recognized, and a subtotal parathyroidectomy is performed preserving part of the gland that appears normal. On the other hand, in MIP the parathyroid adenoma is excised by unilateral exploration through a small cervical incision, often under local anesthesia [18]. In this surgical procedure, the role of preoperative localization of the adenoma is of crucial importance. In our case, although the size of the adenoma was enormously large, we managed to excise it through a rather small incision, following the rules of MIP. It is not obvious whether such a huge adenoma was excised in the past using minimal invasive parathyroidectomy or not.

Preoperative localization of the adenoma followed by intraoperative quality control of the surgical excision based on intraoperative serum levels of IOIPTH became the gold standard of MIP [20]. In comparison to standard bilateral neck exploration MIP is equally effective in achieving normocalcemia. In additional MIP is associated with minimal complications, shorter hospitalization, better cosmetic outcome, and, more importantly, incidence of post-operative transient hypoparathyroidism is limited to 5% [21]. This method is widely accepted and adopted by many centers specialized in endocrine surgery. The protocol is quite strict and includes blood samples before the skin incision (preoperative baseline level) and at 10 and 20 minutes after excision of the adenoma. The 20-minute sample is taken when there is a marked but inadequate drop in 10 minutes comparing to preoperative level. According to the Miami criteria, a 50% or more reduction of IOIPTH compared to the preoperative level is indicative of the removal of the adenoma [22,23]. In our case IOIPTH at 10 minutes after excision decreased at approximately 50% of the preoperative level and became normal 20 minutes after excision. Postoperatively PTH and calcium levels must be measured as in some cases...
calcium supplementation is necessary in order to avoid clinical hypocalcemia [24]. In our case, postoperative hungry bone syndrome was treated successfully. Despite the fact that giant adenomas are rare, protocols of postoperative PTH sampling and hungry bone syndrome treatment are commonly described.

Giant parathyroid adenomas are considered by several authors as a distinct clinical entity with specific genomic aberrations [6]. These adenomas occur more frequently in males and their weight correlates directly to their functionality. Nevertheless, patients remain asymptomatic for a long period that allows the adenoma to grow large prior to detection. In the literature, there are very limited case reports on the topic of non-functioning giant parathyroid adenomas [25,26]. Furthermore, giant parathyroid adenomas have features similar to parathyroid carcinomas and adenomas. In relation to small adenomas, they often present with parafibromin expression, gain of chromosome 5 and loss of adenomatous polyposis coli immunoreactivity [27]. They also mimic carcinomas in terms of glandular size and profound hypercalcemia. Although many researchers have questioned whether giant parathyroid adenomas possess a malignant potential, no recurrences have been noted in literature. However, it is advisable that patients with atypical adenomas attend a close follow-up [6]. In our case, although the adenoma was extremely large, no evidence of malignancy was observed.

Conclusions

In conclusion, this is an extremely rare case of a giant solitary parathyroid adenoma. Diagnosis of such a giant hyperfunctioning solitary parathyroid adenoma is based on clinical presentation, biochemical profile, and imaging studies. Selective treatment is based on surgical excision combined with IOiPTH levels measurement.

Department and Institution where work was done

Fourth Surgical Department, Aristotle University of Thessaloniki, General Hospital “G. Papanikolaou”, Thessaloniki, Greece

Conflict of interest

None.

References:

1. Duan K, Gomez Hernandez K, Mete O: Clinicopathological correlates of hyperparathyroidism. J Clin Pathol, 2015; 68(10): 771–77
2. Wienieke JA, Smith A: Parathyroid adenoma. Head Neck Pathol, 2008; 2(4): 305–8
3. Adami S, Marcocci C, Gatti D: Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res, 2002; 7(Suppl. 2): N18–23
4. Patel KN, Case R: Intraoperative parathyroid hormone monitoring: Optimal utilization. Surg Oncol Clin N Am, 2016; 25(1): 91–101
5. Fraser WD: Hyperparathyroidism. Lancet (London, England), 2009; 374(9684): 145–58
6. Rutledge S, Harrison M, O’Connell M et al: Acute presentation of a giant intrathyroidal parathyroid adenoma: A case report. J Med Case Rep, 2016; 10(1): 286
7. Lalanne-Mistrih ML, Ognois-Ausse P, Goudet P, Cougard P: Giant parathyroid tumors: Characterization of 26 glands weighing more than 3.5 grams. Ann Chir, 2002; 127(3): 198–202 [in French]
8. Gurrado A, Piccinni G, Lissidini G et al: Hypercalcaemic crisis due to primary hyperparathyroidism – a systematic literature review and case report. Endokrynol Pol, 2012; 63(4): 494–502
9. Madkhali T, Alhefdhi A, Chen H, Elfenbein D: Primary hyperparathyroidism. Ulus Cerrahi Derg, 2016; 32(1): 58–66
10. Araujo Castro M, López AA, Fragueiro LM, Garcia NP: Giant parathyroid adenoma: Differential aspects compared to parathyroid carcinoma. Endocrinol Diabetes Metab Case Rep, 2017; 2017: pii: 17-0041
11. Taghavi Kojidi H, Vagharimehr N, Mohseni S et al: Unusual ectopic parathyroid adenoma: A case report. Acta Medicine Iran, 2016; 54(8): 547–50
12. Salsamanis G, Gkousis K, Samaras S et al: Surgical management of a giant parathyroid adenoma through minimal invasive parathyroidectomy. A case report. Int J Surg Case Rep, 2017; 31: 262–63
13. Johnson NA, Toulbin ME, Ogilvie JB: Parathyroid imaging: Technique and role in the preoperative evaluation of primary hyperparathyroidism. Am J Roentgenol 2007; 188(6): 1706–15
14. Carneiro DM, Solorzano CC, Nader MC et al: Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: Which criterion is the most accurate? Surgery, 2003; 134(6): 793–79
15. Palestro CI, Tomas MB, Tronco GG: Radionuclide imaging of the parathyroid glands. Semin Nucl Med, 2005; 35(4): 66–76
16. Low RA, Katz AD: Parathyroidectomy via bilateral cervical exploration: A retrospective review of 866 cases. Head Neck, 1998; 20: 583–87
17. Allendorf I, DiGorgi M, Spanknebel K et al: 1112 consecutive bilateral neck explorations for primary hyperparathyroidism. World J Surg, 2007; 31: 2075–80
18. Mekel M, Mahajna A, Ish-Shalom S et al: Minimally invasive surgery for treatment of hyperparathyroidism. Israel Medical Association Journal, 2005; 7(5): 323–27
19. Pelizzo MR, Pagetta C, Piotto A et al: Surgical treatment of primary hyperparathyroidism: From bilateral neck exploration to minimally invasive surgery, Minerva Endocrinol, 2008; 33(2): 85–93
20. Chen H, Mack E, Starling JR: A comprehensive evaluation of perioperative adjuncts during minimally invasive parathyroidectomy: Which is most reliable? Ann Surg, 2005; 242: 375–80
21. Barczyński M, Golkowski F, Nawrot T: The current status of intraoperative iPTH assay in surgery for primary hyperparathyroidism. Gland Surg, 2015; 4(1): 36–43
22. Carneiro DM, Solorzano CC, Nader MC et al: Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: Which criterion is the most accurate? Surgery, 2003; 134: 973–79
23. Farley RD: Technetium-99m 2-methoxyisobutyl isonitrile-scntigraphy: Preoperative and intraoperative guidance for primary hyperparathyroidism. World J Surg, 2004; 28(12): 1077–110
24. Singh Opinia NM, Rodriguez-Gutierrez R, Maraka S et al: Outcomes of parathyroidectomyn in patients with primary hyperparathyroidism: A systematic review and meta-analysis. World J Surg, 2016; 40(2): 2359–77
25. Diom E, Fagan J, Govender D: Giant cystic parathyroid adenoma masquerading as a retropharyngeal abscess. Otolarngology, 2014; 4(1): 154
26. Kiverini E, Kazi R, Rhys-Evans P, Nippah R: Airway obstruction due to giant non-parathyroid hormone producing parathyroid adenoma. J Cancer Res Ther, 2008; 4: 197–99
27. Sulaiman L, Nilsson IL, Juhlin CHF et al: Genetic characterization of large parathyroid adenomas. Endocr Relat Cancer, 2012; 19(3): 389–407